RICHARD YOUNG: Open Payments
NPI 1417371881 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,712 in 134 payments from 12 companies in 2025. Trend: 2023 $2,415 · 2024 $1,793 · 2025 $2,712
Food & beverage: $2,491Education: $221
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 33 | $688 |
| Otsuka America Pharmaceutical, Inc. | 21 | $618 |
| Janssen Pharmaceuticals, Inc | 11 | $343 |
| E.R. Squibb & Sons, L.L.C. | 23 | $300 |
| Neurocrine BioSciences, Inc. | 10 | $237 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $231 |
| ABBVIE INC. | 10 | $141 |
| Alkermes, Inc. | 3 | $54 |
| Vanda Pharmaceuticals Inc. | 3 | $53 |
| Corium, LLC | 1 | $17 |
Products named: UZEDY, ABILIFY MAINTENA, COBENFY, ABILIFY ASIMTUFII, INGREZZA, CAPLYTA, INVEGA SUSTENNA, INVEGA.
Industry payments across TX — which companies pay providers there.
